All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
Lymphoma Hub Satellite Symposium at 15-ICML: New chemotherapy-free approaches for the treatment of lymphoid malignancies
The Lymphoma Hub Satellite Symposium at 15-ICML is bringing together an international panel of experts to discuss the novel chemotherapy-free treatment approaches for lymphoid malignancies.
Presentations will focus on diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic lymphoma, navigating the rapidly evolving treatment landscapes. The new chemotherapy-free treatment options will be explored alongside the current standards of care. Each presentation will be followed by a question and answer session to allow for discussion with the expert panel.
Can we switch to chemo-free? Submit your question for the panel today and come and join the debate at 15-ICML!
When: Tuesday 18 June 2019, 18:30–20:00
Where: USI Lugano Campus, (University) Auditorium, Via Buffi 13, 6900 Lugano, Switzerland
Visit the website for more information: www.icml.lymphomahub.com/
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
In practice, what is the most common reason you discontinue rituximab maintenance after BR in older patients with previously untreated MCL?